Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8109MR)

This product GTTS-WQ8109MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8109MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12069MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ2364MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ10961MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ943MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ15627MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ13835MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ12589MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ12643MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW